


65. Fenaroli P, Maritati F, Vaglio A. Into Clinical Practice: Diagnosis and Therapy of Retroperitoneal Fibrosis. *Curr Rheumatol Rep.* 2021 Feb 10;23(3):18. doi:10.1007/s11926-020-00966-9. PMID: 33569638.
66. Nikiphorou E, Galloway J, Fragoulis GE. Overview of IgG4-related aortitis and periaortitis. A decade since their first description. *Autoimmun Rev.* 2020 Dec;19(12):102694. doi:10.1016/j.autrev.2020.102694.
67. Marvisi C, Accorsi Buttini E, Vaglio A. Aortitis and periaortitis: The puzzling spectrum of inflammatory aortic diseases. *Presse Med.* 2020 Apr;49(1):104018. doi:10.1016/j.lpm.2020.104018.
68. Shinoda K, Taki H, Sugiyama T. Recurrence of IgG4-related disease following treatment with rituximab. *Mod Rheumatol.* 2013; 23 (6): 1226-1230.
69. Wallace ZS, Mattoo H, Mahajan VS et al. Predictors of disease relapse in IgG4-related disease following rituximab. *Rheumatology (Oxford)* 2016; 55 (6): 1000-1008
70. Campochiaro C, Della-Torre E, Lanzillotta M et al. Long-term efficacy of maintenance therapy with Rituximab for IgG4-related disease. *Eur J Intern Med* 2019; S0953-6205(19)30467-4. doi:10.1016/j.ejim.2019.12.029
71. Majumder S, Mohapatra S, Lennon RJ et al. Rituximab Maintenance Therapy Reduces Rate of Relapse of Pancreaticobiliary Immunoglobulin G4-related Disease. *Clin Gastroenterol Hepatol.* 2018;16(12):1947-1953. doi:10.1016/j.cgh.2018.02.049.
72. Yamamoto M, Awakawa T, Takahashi H. Is rituximab effective for IgG4-related disease in the long term? Experience of cases treated with rituximab for 4 years. *Ann Rheum Dis.* 2015; 74 (8):e46.
73. Della-Torre E, Lanzillotta M, Campochiaro C et al. Efficacy and safety of rituximab biosimilar (CT-P10) in IgG4-related disease: an observational prospective open-label cohort study. *Eur J Intern Med.* 2021 Feb;84:63-67. doi:10.1016/j.ejim.2020.12.006.
74. Khan ML, Colby TV, Viggiano RW, Fonseca R. Treatment with bortezomib of a patient having hyper IgG4 disease. *Clin Lymphoma Myeloma Leuk.* 2010; 10(3):217-219.
75. Jalaj S, Dunbar K, Campbell A et al. Treatment of Pediatric IgG4-Related Orbital Disease With TNF- α Inhibitor. *Plast Reconstr Surg.* 2018 Jan/Feb;34(1):e10-e12.
76. Poo SX, Pepper RJ, Onwordi L et al. Sirolimus use in patients with subglottic stenosis in the context of granulomatosis with polyangiitis (GPA), suspected GPA, and immunoglobulin G₄-related disease. *Scand J Rheumatol.* 2021;50(1):52-57. doi:10.1080/03009742.2020.1777324.
77. Takanashi S, Kaneko Y, Takeuchi T. Effectiveness of takrolimus on IgG4-related disease. *Mod Rheumatol.* 2019;29(5):892-894. doi:10.1080/14397595.2018.1532560.
78. Peng L, Zhang P, Zhang X, et al. Clinical features of immunoglobulin G4-related disease with central nervous system involvement: an analysis of 15 cases. *Clin Exp Rheumatol.* 2020;38(4):626-632. Epub 2020 Feb 14 P
79. Yamamoto M, Takahashi H, Takano K et al. Efficacy of abatacept for IgG4-related disease over 8 months. *Ann Rheum Dis.* 2016;75(8):1576-8. doi:10.1136/annrheumdis-2016-209368.
80. Lanzillotta M, Fernández-Codina A, Culver E et al. Emerging therapy options for IgG4-related disease. *Expert Rev Clin Immunol.* 2021 May;17(5):471-483. doi:10.1080/1744666X.2021.1902310.
81. Della-Torre E, Lanzillotta M, Yacoub MR. Dupilumab as a <i>potential</i> steroid-sparing treatment for IgG4-related disease. *Ann Rheum Dis.* 2020 Jan14: annrheumdis-2020-216945. doi:10.1136/annrheumdis-2020-216945. Epub ahead of print.
82. Yamamoto M, Yoshikawa N, Tanaka H. Efficacy of dupilumab reveals therapeutic target for IgG4-related disease: simultaneous control of inflammation and fibrosis. *Ann Rheum Dis.* 2020 Feb 7:annrheumdis-2020-217076. doi:10.1136/annrheumdis-2020-217076. Epub ahead of print.
83. Simpson RS, Lau SKC, Lee JK. Dupilumab as a novel steroid-sparing treatment for IgG4-related disease. *Ann Rheum Dis.* 2020 Apr;79(4):549-550. doi:10.1136/annrheumdis-2019-216368. Epub 2019 Dec 19. PMID: 31857343.
84. Hoy SM. Dupilumab: A Review in Chronic Rhinosinusitis with Nasal Polyps. *Drugs.* 2020 May;80(7):711-717. doi:10.1007/s40265-020-01298-9. PMID: 32240527
85. Chovančová Z. IgG4 podřída imunoglobulinů a s ní související patologické stavy aneb jak účinně imitovat nádorové onemocnění. *Klinická onkologie, přijato do tisku.*
86. Chovančová Z. Immunosenescence - the sunset over the immune system. *Vnitř. Lék.* 2020;66(6):353-358.

Víte, že listovačky časopisu Klinická farmakologie a farmacie jsou volně dostupné on-line?



V posledních číslech
najdete tato
hlavní témata:

- Imunologie (2/2022)
- Chirurgie (1/2022)
- Revmatologie (4/2021)
- Hematologie (3/2021)
- Farmakoterapie v kardiologii (2/2021)

... a mnoho článků z jiných
oblastí medicíny a farmacie

www.klinickafarmakologie.cz



Mohou být přínosné i pro vás...